Kairos Pharma Ltd. (NYSE American: KAPA) announced the addition of Huntsman Cancer Institute in Salt Lake City, Utah, as a new site for its Phase 2 clinical trial of ENV105. This trial is focused on treating castrate-resistant prostate cancer patients.
The inclusion of Huntsman Cancer Institute expands the geographic reach and patient access for the ongoing randomized trial. This expansion is a step towards accelerating patient enrollment and gathering comprehensive data for ENV105.
ENV105 is Kairos Pharma's lead candidate, an antibody that targets CD105, a protein identified as a key driver of resistance to various cancer treatments. Expanding trial sites is crucial for advancing its development in addressing significant unmet medical needs.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.